Adaptive drug technology developer Senti has completed a New Enterprise Associates-led series A round that included Amgen Ventures.

US-based synthetic biology technology startup Senti Biosciences has closed a $53m series A round that included Amgen Ventures, the strategic investment arm of pharmaceutical company Amgen.

The round was led by venture capital firm New Enterprise Associates and also featured Pear Ventures, Lux Capital, Menlo Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital and LifeForce Capital.

Senti is working on technology that will facilitate the creation of synthetic gene circuits to help in the development of adaptive cell and…